Trial of retinol and isotretinoin in skin cancer prevention: A randomized, double-blind, controlled trial

Norman Levine, Thomas E. Moon, Brenda Cartmel, Jerry L. Bangert, Steven Rodney, Qiong Dong, Yei Mei Peng, David S. Alberts

Research output: Contribution to journalArticle

95 Scopus citations

Abstract

The objective of this study was to examine the effect of retinol and isotretinoin on the incidence of nonmelanoma skin cancer in high-risk subjects. A total of 525 participants with a history of at least four basal cell carcinomas (BCCs) and/or cutaneous squamous cell carcinomas (SCCs) were entered into a randomized, double-blind, placebo-controlled trial, performed in free-standing study clinics. Participants were randomly assigned to receive oral retinol (25,000 units), isotretinoin (5-10 mg), or placebo supplementation daily for 3 years. The time to first new occurrence of BCC or cutaneous SCC was used as the outcome measure. During the study period, 319 BCCs and 125 cutaneous SCCs were diagnosed clinically and pathologically. There were no differences between those who received retinol, isotretinoin, or the placebo, with regard to the time to first occurrence or to the total number of tumors noted. No beneficial effects were noted with regard to the prevention of nonmelanoma skin cancer with either retinol or isotretinoin.

Original languageEnglish (US)
Pages (from-to)957-961
Number of pages5
JournalCancer Epidemiology Biomarkers and Prevention
Volume6
Issue number11
StatePublished - Nov 20 1997

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Fingerprint Dive into the research topics of 'Trial of retinol and isotretinoin in skin cancer prevention: A randomized, double-blind, controlled trial'. Together they form a unique fingerprint.

  • Cite this

    Levine, N., Moon, T. E., Cartmel, B., Bangert, J. L., Rodney, S., Dong, Q., Peng, Y. M., & Alberts, D. S. (1997). Trial of retinol and isotretinoin in skin cancer prevention: A randomized, double-blind, controlled trial. Cancer Epidemiology Biomarkers and Prevention, 6(11), 957-961.